López Abente, JacoboBenito Villalvilla, CristinaJaumont, XavierPfister, PascalTassinari, PaoloPalomares Gracia, Óscar2024-01-252024-01-252021López-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs. Eur Respir J. 2021 Jan 14;57(1):2000751. doi: 10.1183/13993003.00751-20200903-193610.1183/13993003.00751-2020https://hdl.handle.net/20.500.14352/95318IgE-FcεR1 cross-linking on human pDCs impairs their capacity to generate regulatory T-cells and in vitro omalizumab restores this ability. These findings may pave the way for novel biomarkers to assess omalizumab clinical efficacy and responder patients.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://doi.org/10.1183/13993003.00751-2020https://pubmed.ncbi.nlm.nih.gov/32675208/restricted access577.1OmalizumabIgEPlasmacytoid dendritic cellsRegulatory T cellsBioquímica (Medicina)Bioquímica (Química)Inmunología2403 Bioquímica2302 Bioquímica2412 Inmunología3207.01 Alergias